Abstract:Glioblastoma is a most aggressive brain tumor with a median overall survival of less than two years. The current treatment is surgery, chemotherapy, and radiotherapy. However, glioblastoma is difficult to treat and recurs some time after treatment. Several reports have shown that intratumoral heterogeneity is a hallmark of glioblastoma, and it is often said to be a factor that contributes to tumor progression and tumor relapse. Based on the single-cell gene expression profiling, glioblastoma is found to be composed of tumor cells with three different subtype signatures namely proneural, classical, and mesenchymal. These subtypes may transition between each other, which may be affected, and/or potentially controlled, by genetic and epigenetic modifications. Even microenvironmental events and communication between different subtype cells within the same tumor may play a role. Studies in this thesis focused on identifying regulators of subtype transitions and their involvement in cell-to-cell communication in individual glioblastomas. Study I used several analytical approaches including connectivity map analysis, overexpression screen, RNA-sequencing, and gene expression profiling. SOX2 was identified to have the capacity to transition mesenchymal gene expression subtype glioblastoma cells back to a non-mesenchymal signature. Subsequently, SFRP2 was identified as a SOX2 antagonist able to induce a mesenchymal transition. In line with this, SFRP2 was found expressed at a higher level in mesenchymal as compared to proneural and classical TCGA glioblastoma samples. In vitro, SFRP2 decreased tumor sphere formation and cell proliferation, and increased cell invasion capacity and sensitivity towards apoptotic stimuli. Spatial gene expression analysis found SFRP2correlated genes to be expressed in a higher level in vascularized areas in glioblastoma, as opposed to SOX2-correlated genes that were highly expressed in cellular tumor regions. Moreover, conditioned media from SFRP2 transitioned cells induced more MRC1 (encodes CD206) expression in human monocytes in vitro. Collectively, these experiments identified SFPR2 as a SOX2 antagonist and inducer of mesenchymal transition in glioblastoma. In Study II PROX1 was found expressed at a lower level in glioblastoma as compared to lowgrade gliomas. Tumors with lower PROX1 correlated with a mesenchymal subtype and patients exhibited shorter survival. Suppression of PROX1 in glioblastoma cell lines with high PROX1 levels induced transition to a mesenchymal glioblastoma subtype signature. Conversely, overexpression of PROX1 transitioned cells to a non-mesenchymal subtype signature. In co-occurrence with these transitions, PROX1 functionally impacted on cell proliferation and levels of several cell cycle proteins. SOX2 was identified as an upstream signaling component of PROX1, and thus SOX2 and PROX1 levels decreased upon treatment with a CDK inhibitor. By co-immunoprecipitation experiments PROX1 was found to interact with THRAP3 in the nucleus. Depletion of THRAP3 increased PROX1 expression and protein stability. Based on previous reports on THRAP3, these findings suggest THRAP3 to be involved in the transcriptional regulation of PROX1. These results underscore a functional role of PROX1 in glioblastoma development and with implications for survival outcome. In study III the well-known U-343 cell line system was used as a model system to study intratumoral heterogeneity and cell-to-cell communication. The four cell lines U-343 MG, U343 MGa, U-343 MGa 31L and U-343 MGa Cl2:6 are derived from the same glioblastoma, and display different phenotypes including marker expression, cells shape, and proliferation. Gene expression and DNA copy number analyses suggested their shared derivations from a common ancestor in a tumor evolutionary relationship. Temozolomide (TMZ) sensitivity of the individual cell lines was determined. In a cell culture composed of a mixture of all four cell lines, the one with the lowest sensitivity outlived the others during TMZ treatment, which modeled the appearance of drug resistance. Finally, co-culture and conditioned media experiments revealed complex interactions between the U-343 cell lines through signaling by cell-to-cell contact or secreted proteins. These findings provide a model for research on intratumoral heterogeneity, both with regard to appearance of drug resistance and to interclonal interactions. Collectively, these studies provide insights into the complexity of intratumoral heterogeneity, including subtype transitions during tumor progression and interclonal communication. Intratumoral heterogeneity is thus important to consider when designing new therapeutic strategies and may also in itself pose novel therapeutic targets.

Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype

Table S4 from Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype

PROX1 promotes human glioblastoma cell proliferation and invasion via activation of the nuclear factor-κB signaling pathway.

Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis

Prospero Homeobox 1 Promotes Proliferation, Migration, and Invasion of Osteosarcoma Cells and Its Clinical Significance

Abstract 554: Determining the role of PROX1 in prostate cancer neuroendocrine trans-differentiation

Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1α Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma

SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma

LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification

Impact of an Altered PROX1 Expression on Clinicopathology, Prognosis and Progression in Renal Cell Carcinoma

The Role of Lymphatic Marker Prox-1 in Relation to Brain Tumours

PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance

Intratumoral heterogeneity in glioblastoma: subtype transition and cell-to-cell communication

PROX1 Promotes Hepatocellular Carcinoma Metastasis by Way of Up-Regulating Hypoxia-Inducible Factor 1α Expression and Protein Stability.

Prox1 Suppresses the Proliferation of Breast Cancer Cells via Direct Inhibition of c-Myc Gene Expression

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targets

Abstract A026: PROX1 transcription factor regulates rhabdomyosarcoma growth, myogenic properties and therapeutic targets

PROX1-mediated epigenetic silencing of SIRT3 contributes to proliferation and glucose metabolism in colorectal cancer

Six1 Expression is Associated with A Poor Prognosis in Patients with Glioma

Abstract 1095: Prox1 transcription factor and its downstream signaling - A new therapeutic target for rhabdomyosarcoma